QUASENSE Drug Patent Profile
✉ Email this page to a colleague
When do Quasense patents expire, and when can generic versions of Quasense launch?
Quasense is a drug marketed by Watson Labs and is included in one NDA.
The generic ingredient in QUASENSE is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
Summary for QUASENSE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 5 |
Patent Applications: | 277 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for QUASENSE |
DailyMed Link: | QUASENSE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for QUASENSE
US Patents and Regulatory Information for QUASENSE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Watson Labs | QUASENSE | ethinyl estradiol; levonorgestrel | TABLET;ORAL | 077101-001 | Sep 6, 2006 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |